🩺 HUM $6.81M Stock-and-Options Cross Loads the $400 Calls Into the October Star Ratings Window — Don't Call This a Clean Bullish Bet

📅 2026-08-12 | 🔥 Unusual Activity Detected

✅ Updated 2026-08-13 pre-market — the next-day OPRA open interest confirmed both strikes opened, with one landing above our number and one below. The September $400 call rose 134 → 1,617 (+1,483) against a 1,000-lot print — 148% of size, so other buyers layered on. The October $400 call rose 228 → 1,738 (+1,510) against 2,000 printed — 76% of size, so roughly a quarter of the October volume was a transfer between existing holders rather than new contracts. Both BTO labels stand; the October position is real but smaller than the headline size implied. See the ✅ RESOLVED box.

---

🎯 The Quick Take

Three times today, a desk bought Humana $400 calls — 1,000 lots each — for a combined ≈$6.81 million, split ≈$1.55M into the September 18 expiration and ≈$5.26M into October 16. All three printed as stock-and-options crosses, meaning shares traded alongside the calls with a known counterparty on the other side. That paired share leg means the calls alone do not tell us this was a bullish bet — what they do tell us is that two-thirds of the money is pointed squarely at the one window that contains Humana's biggest event of the year: the CMS Star Ratings release.

---

🏢 Company Overview

Humana Inc. (NYSE: HUM) is a Health Care / Managed Health Care company that runs almost entirely on Medicare Advantage economics, per its company profile. It reports through two segments: Insurance — the Medicare Advantage, prescription drug, and specialty insurance business that produced $820 million of GAAP operating income in Q2 2026 alone, per the Q2 2026 release — and CenterWell, the care-delivery arm covering senior primary care, pharmacy, and home health.

Humana finished Q2 2026 with 7.2 million Medicare Advantage members and was on track to potentially become the largest MA insurer by year-end, per Healthcare Dive. Market cap sits at $46.04 billion, per stockanalysis.com, and the stock has been on a wild ride: +49.1% year to date from a $256.35 close on December 31, 2025, per MarketBeat, against a 52-week range of $163.11–$428.88, per stockanalysis.com. Because nearly the entire equity story is Medicare Advantage, three variables drive this stock: the medical loss ratio, CMS rate updates, and Star Ratings — the exact issue behind today's flow.

---

💰 The Option Flow Breakdown

📊 What Just Happened

All three legs bought the same $400 strike call, priced as stock-and-options crosses 🤝 — negotiated blocks with a paired equity leg, not lit sweeps. No urgency, no panic buying — a broker matched this off the open book against a known counterparty.

Worth flagging: the October $400 call was bought twice, and the second buy cost 13.5% more than the first — $24.64 at 09:53:44, then $27.97 at 11:13:29 — as Humana climbed from $378.00 to $382.38 intraday, a +2.85% day against a $372.82 prior close. Whoever built this position kept paying up as the stock ran, rather than waiting for a pullback. Two-thirds of the total premium — ≈$5.26M of $6.81M — went into the October window, versus ≈$1.55M into September.

✅ RESOLVED — Both Strikes Opened; October Captured 76%, September 148%

Updated 2026-08-13 pre-market. Resolving OPRA snapshot timestamped August 13 (reflects the August 12 close, after this print); baseline is the August 12 snapshot (reflects the August 11 close, before this print).

Direction is settled on both legs: open, not close. Neither line fell, and both cleared their prior open interest, so the "proven open" read from the size-versus-OI rule held.

But the October leg is materially smaller than the print suggested. We predicted ≈2,228 and got 1,738 — ≈490 contracts short, meaning roughly 25% of the October volume matched against existing holders trimming rather than creating new contracts. That is exactly the transfer case the callout warned about. If you were sizing the October star-ratings bet off the 2,000-lot headline, the honest number of genuinely new October contracts is 1,510.

September ran the other way. +1,483 against a 1,000 print means ≈483 contracts of additional buying arrived at the September strike beyond the block we captured. Combined net new exposure across both expirations is +2,993 contracts, against 3,000 printed — so at the package level the capture is 99.8%, even though the split between expirations moved.

Unchanged: this printed as a stock-and-options cross, so the BUY tags are reported, not tape-proven, and the paired share leg means the package may be far less directional than the call strikes alone suggest.

---

🤓 What This Actually Means — Plain English

A stock-and-options cross is not the same as a call buyer making a directional bet. When a trade prints this way, it means shares of Humana traded alongside the option contracts in the same negotiated package, off the public order book, with both sides agreeing on price in advance. That paired stock leg can offset some or all of the calls' upside exposure — the package could be a delta-hedged long-volatility position (own the calls, short enough stock to neutralize day-to-day direction, and profit if Humana moves a lot either way around the Star Ratings news), a financing or conversion structure, or a facilitated risk transfer between two institutions. We did not pull the paired equity leg's share count today, so we cannot tell you which of those it is — only that "someone bought $6.81M of bullish calls" is the wrong headline. What we can say with confidence is that this package is now exposed to whatever happens to HUM around October 15–16.

On the money itself: every dollar of this $6.81M is 100% time value. The $400 strike sits well above a $383-ish stock — these calls have zero intrinsic value. That means if Humana closes anywhere at or below $400 on expiration day, both the September and October contracts expire completely worthless, and the entire $6.81 million premium is gone. There is no floor, no partial recovery — this is pure options decay risk stacked on top of directional risk.

And the bar to actually profit is higher than the $400 strike suggests. Once you add in what was paid for the calls, the blended October breakeven works out to ≈$426.31 — a stock has to close above that price on October 16 for the October calls to show a net profit, not just above $400. That $426.31 breakeven sits essentially at Humana's 52-week high of $428.88. In plain terms: this position doesn't pay off on "Humana goes up a little" — it needs Humana to make a new 52-week high, and by a meaningful margin, inside the next 65 days. The September leg's breakeven is a comparatively closer $415.50, but that expiration — as the section below lays out — has nothing scheduled to move the stock that far.

---

📈 Technical Setup / Chart Check-Up

YTD chart

Humana has been one of 2026's biggest re-rating stories — up 49.1% year to date — but the last month has been choppy: a $404.34 close on July 21 gave way to a ≈8% drop on July 29's Q2 print, and the stock has since traded a $362–$386 band with daily swings routinely running ±3% to ±5%, well above its 0.74 beta would suggest.

Gamma-based support & resistance analysis

Spot at the time of this pull was $384.27. Being straightforward with you here: the options chain did not return any material gamma support or resistance levels for HUM today — no clean call wall, put wall, or hedge wall stood out from the noise in the strike-by-strike gamma exposure data. The nearest concentration of total gamma sits around the $370–$385 strikes (where the stock is currently trading) with the $355 and $370 strikes showing the largest put-side gamma and $410–$450 showing scattered call-side gamma further out — but none of it rose to the level of a dependable wall. Translation: don't lean on dealer-hedging levels to trade this name right now; they aren't giving a clean signal.

Implied move

Options pricing is baking in real movement, and it scales up fast the further out you look:

• To August 14 (2 days): ±3.33%, range $371.64 – $397.26
• To August 21 (9 days): ±7.22%, range $356.69 – $412.21
• To September 18 (37 days — the September expiration): ±14.65%, range $328.14 – $440.76

Notice that the September expiration's own implied-move range ($328.14 – $440.76) comfortably contains the $400 strike on both sides — the market is pricing HUM as capable of getting there on vol alone, with or without a hard catalyst. That's useful context for why a desk might still buy September optionality even though, as the next section shows, nothing is scheduled to happen inside that window.

---

🎪 Catalysts

Already Happened (Q2 defines the setup)

Humana reported Q2 2026 results on July 29, 2026 — a clean double beat: adjusted EPS $7.61 vs. $7.27 consensus, revenue $40.87B vs. $40.58B consensus, per the Q2 2026 release and MarketBeat, with a benefit ratio of 91.2%, in line with the "slightly above 91%" guide. The stock fell ≈8% anyway — the beat wasn't the story. Humana disclosed it will exit 2027 plans covering ≈600,000 members, roughly 8% of its 7.2 million MA base, hoping to recapture about 240,000 of them, per Healthcare Dive, and CEO Jim Rechtin refused to guarantee 2028 Star Ratings quartile standings, saying "We cannot guarantee an outcome," per Healthcare Dive.

⚠️ A derived number worth sitting with: Q1's 89.4% benefit ratio and Q2's 91.2% average to ≈90.3% for the first half. To land the affirmed full-year guide of 92.75% ± 25 bps, per the Q2 release, the second half needs to run at ≈95% — a step-up of roughly 4.7 percentage points, entirely untested and entirely contained in the Q3 and Q4 prints. This is our derivation, not a company disclosure, and it's the cleanest quantitative bear argument in the name.

On the regulatory side, CMS finalized CY2027 Medicare Advantage rates on April 7, 2026 at +2.48%, versus +0.09% originally proposed, and dropped the punitive risk-model recalibration entirely — Jefferies called the relief "hard to overstate," per Healthcare Dive. Separately, CMS's April 3, 2026 Star Ratings overhaul eliminated 11 administrative metrics, but most of that relief applies to ratings released in 2029 — it will not rescue an October 2026 print, per Healthcare Dive. Humana also lost its own lawsuit challenging its 2025 Star Ratings, per the Q2 release.

Upcoming — Keep Catalyst Dates and Expiration Dates Separate

The Star Ratings release is expected in the first half of October — the CEO's own comments about "not guaranteeing" 2028 quartile standings are about precisely this print, per Healthcare Dive, July 29, 2026 — and Medicare open enrollment opens October 15, exactly one day before the October 16 expiration, per KFF. The September 18 expiration contains zero scheduled hard catalysts. Federal MA quality-bonus spending hit $13.4 billion in 2026, with only 68% of enrollees in bonus-qualifying plans, per KFF — this is a large, binary, direct-dollar event for Humana specifically.

⚠️ Honest flag, stated plainly: CMS has not published a confirmed date for the 2027 Star Ratings release. The October timing is inferred from the statutory requirement that ratings be live before the October 15 enrollment window opens, plus coverage describing the ratings as "expected in October" without naming a day, per Healthcare Dive. Treat the specific day as unconfirmed.

Earnings falls outside both expirations, and this matters. Humana has not announced a Q3 2026 date as of August 11, 2026. Precedent — October 30, 2024 and November 5, 2025, per MarketBeat's earnings history — points to ≈October 28–November 5, 2026, roughly two weeks after the October 16 expiration. So this is a regulatory-event structure, not an earnings structure. If someone wanted a defined window on the Star Ratings outcome and the opening days of open enrollment — and nothing else — October 16 is the expiration that does it, and September 18 is not.

Analyst backdrop: thirteen rating or target actions since May 20, 2026, all directionally positive, per MarketBeat's price target history — but with a wide $370–$513 spread. The two most recent actions — Morgan Stanley to $370 on August 4 and JPMorgan to $393 on August 10 — both sit below today's $383.45 spot, same source. The bulls (Leerink $513, Wells Fargo $502, BofA $500, Evercore $480) sit $130–$145 above the incrementalists. That dispersion is exactly the kind of disagreement that shows up in out-of-the-money call buying — but it also means the ≈$426.31 blended October breakeven requires Humana to run past consensus and essentially retest its 52-week high, not just drift higher.

---

🎲 How Different Traders Might Read This

🎲 The YOLO trader

You want in on the Star Ratings binary. Understand what you're buying into: these are already-priced $400 calls with a ≈$426.31 blended October breakeven — you need a fresh 52-week high, not just a good headline. If you're chasing this exact strike, you're buying at a worse price than the desk's first fill ($24.64) and closer to its second ($27.97), on a stock that already ran 2.85% today. Consider whether a slightly further-out-of-the-money strike, sized much smaller than $6.81M, better fits a "binary event" bet than trying to match institutional size.

📈 The swing trader

The September 18 expiration is catalyst-empty by design — its only realistic drivers are stray litigation headlines, more analyst actions, and ordinary ±3–5% chop. If you're not trying to hold through the Star Ratings release itself, that's actually a feature: you get exposure to HUM's elevated realized volatility without betting on a specific, unconfirmed October date. Just remember the September $415.50 breakeven still requires real upside from here, and it's also 100% time value with no floor.

💰 The premium collector

This board is a reminder that HUM's implied volatility is being bid up for a real reason — the September expiration alone is pricing a ±14.65% range. If you're inclined to sell premium here (covered calls above $428.88, or defined-risk credit spreads), be aware you'd be selling into a stock that just gapped from a $362–$386 band and has an unresolved binary sitting in October. Collect premium with position sizing that assumes the ratings news could gap the stock either direction.

🌱 The beginner

Before doing anything with this name: understand that a "$6.81M options buy" headline does not mean "a big investor thinks the stock is going up." These specific trades printed with a paired stock leg attached, which strips out a clean directional read — professionals sometimes build packages that profit from volatility rather than direction. Separately, know that these are 100% out-of-the-money calls: if Humana just sits still or drifts modestly, this entire position expires worthless. Options can lose their full value, and this trade illustrates exactly how that risk works — treat it as a case study, not a signal to copy.

---

⚠️ Honest Limits — What the Tape Cannot Prove

• We cannot prove direction. All three legs printed as stock-and-options crosses — negotiated, off-book, with a known counterparty and a paired equity leg. The reported BUY label describes the option side only; without pulling the equity leg's share count against the package's delta, we cannot say whether this is bullish, a hedge, a financing structure, or a facilitated risk transfer. No directional claim is made here.
• Open/close is proven on size, not certain on substance. Size exceeded prior OI on every leg (1,000 vs. 228, and 1,000 vs. 134), which supports "opening" — but even a clean size-over-OI print can resolve as partly a transfer between existing holders. Tomorrow's ≈06:30 ET OI snapshot is the definitive test; we predicted the specific numbers above.
• The Star Ratings date is not confirmed. This is the single biggest gap in this whole thesis: CMS has not published a date for the 2027 Star Ratings release. "First half of October" is inferred from the statutory requirement that ratings precede the October 15 enrollment open, and from coverage that describes the release as "expected in October" without naming a day. If the release slips past October 16, the entire premise of this being an October-expiration-timed bet weakens.
• Q3 earnings is estimated, not confirmed — no company announcement existed as of August 11, 2026; the ≈October 28–November 5 window is precedent-based only.
• A precise 3-month return could not be computed — accessible daily price history for HUM begins June 2, 2026, so the YTD (+49.1%) and 52-week (+42.37%) figures are used instead of an exact trailing-3-month number.
• No 2026/2027 Investor Day could be verified as scheduled. The only confirmed reference is the CEO's mention of "Investor Day last year" on the Q2 call.
• The Q3 2026 EPS consensus is not usable — MarketBeat shows only 2 contributing analysts with a $0.08–$1.36 range around a $0.72 midpoint; that spread is too wide to treat as a real bar.
• What OPRA truly cannot tell us, ever: the broker or market-maker ID, the identity of the customer, the order ID, whether pre-existing option positions sit behind this trade, or any invisible stock/futures hedge beyond the paired equity leg we already know exists.

These are 100%-time-value calls. Every dollar of the ≈$6.81 million at risk here evaporates if Humana closes at or below $400 on either expiration — there is no intrinsic-value floor. Options trading involves substantial risk of loss and may not be suitable for all investors; nothing in this analysis is a recommendation to buy or sell any security.

---

Last updated: 2026-08-13 (pre-market) — the next-day OPRA open-interest snapshot confirmed both legs as opens. Sep-18 $400C 134 → 1,617 (+1,483 against 1,000, 148% of size) and Oct-16 $400C 228 → 1,738 (+1,510 against 2,000, 76% of size): OPEN (BTO) on both. The October leg came in ≈490 contracts below prediction — roughly a quarter of that volume was a transfer, not new contracts — and the article now says so. The ⏳ callout was replaced with the ✅ RESOLVED box; no title change was required.